Use and impact of inotropes and vasodilator therapy in hospitalized patients with severe heart failure.

[1]  William T. Abraham,et al.  Evaluation study of congestive heart failure and pulmonary artery catheterization effectiveness , 2005 .

[2]  K. Adams,et al.  In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE). , 2005, Journal of the American College of Cardiology.

[3]  William T. Abraham,et al.  Risk stratification for in-hospital mortality in acutely decompensated heart failure. Classification and regression tree analysis , 2005 .

[4]  M. Crouch,et al.  Mortality and length of hospital stay in patients receiving dobutamine, milrinone, or nesiritide for acute decompensated heart failure , 2004 .

[5]  N. Freemantle,et al.  Clinical trials update from the European Society of Cardiology Heart Failure meeting: SHAPE, BRING‐UP 2 VAS, COLA II, FOSIDIAL, BETACAR, CASINO and meta‐analysis of cardiac resynchronisation therapy , 2004, European journal of heart failure.

[6]  N. Freemantle,et al.  Clinical trials update and cumulative meta‐analyses from the American College of Cardiology: WATCH, SCD‐HeFT, DINAMIT, CASINO, INSPIRE, STRATUS‐US, RIO‐Lipids and cardiac resynchronisation therapy in heart failure , 2004, European journal of heart failure.

[7]  Christopher M O'Connor,et al.  Heart failure etiology and response to milrinone in decompensated heart failure: results from the OPTIME-CHF study. , 2003, Journal of the American College of Cardiology.

[8]  N. Freemantle,et al.  The effectiveness and relative effectiveness of intravenous inotropic drugs acting through the adrenergic pathway in patients with heart failure—a meta‐regression analysis , 2002, European journal of heart failure.

[9]  R. Califf,et al.  Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. , 2002, JAMA.

[10]  V. Hasselblad,et al.  Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness (ESCAPE): design and rationale. , 2001, American heart journal.

[11]  A. Maggioni,et al.  Intermittent 6-month low-dose dobutamine infusion in severe heart failure: DICE multicenter trial. , 1999, American heart journal.

[12]  R. Califf,et al.  Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: insights from the Flolan International Randomized Survival Trial (FIRST). , 1999, American heart journal.

[13]  M. Lishner,et al.  Intermittent dobutamine treatment in patients with chronic refractory congestive heart failure: A randomized, double‐blind, placebo‐controlled study , 1998, Clinical pharmacology and therapeutics.